lestaurtinib has been researched along with olomoucine in 1 studies
| Studies (lestaurtinib) | Trials (lestaurtinib) | Recent Studies (post-2010) (lestaurtinib) | Studies (olomoucine) | Trials (olomoucine) | Recent Studies (post-2010) (olomoucine) |
|---|---|---|---|---|---|
| 124 | 12 | 63 | 227 | 0 | 24 |
| Protein | Taxonomy | lestaurtinib (IC50) | olomoucine (IC50) |
|---|---|---|---|
| Chain A, MAP KINASE P38 | Homo sapiens (human) | 27 | |
| Chain A, PROTEIN (MAP KINASE P38) | Homo sapiens (human) | 27 | |
| Chain A, PROTEIN (MAP KINASE P38) | Homo sapiens (human) | 27 | |
| Chain A, Protein (map Kinase P38) | Homo sapiens (human) | 27 | |
| Chain A, Extracellular Regulated Kinase 2 | Rattus norvegicus (Norway rat) | 27 | |
| Chain A, Extracellular Regulated Kinase 2 | Rattus norvegicus (Norway rat) | 27 | |
| G2/mitotic-specific cyclin-B2 | Homo sapiens (human) | 7 | |
| G1/S-specific cyclin-E2 | Homo sapiens (human) | 7.8 | |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | 7 | |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | 6.7875 | |
| Cyclin-dependent kinase 4 | Homo sapiens (human) | 7 | |
| G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 7 | |
| G2/mitotic-specific cyclin-B | Marthasterias glacialis (spiny starfish) | 5.2571 | |
| Cyclin-A2 | Homo sapiens (human) | 7.75 | |
| G1/S-specific cyclin-D1 | Homo sapiens (human) | 7 | |
| G1/S-specific cyclin-E1 | Homo sapiens (human) | 6.4436 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 6.5945 | |
| Mitogen-activated protein kinase 1 | Homo sapiens (human) | 7 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 7 | |
| Cyclin-A1 | Homo sapiens (human) | 7.75 | |
| Cyclin-dependent-like kinase 5 | Homo sapiens (human) | 4.6 | |
| Cyclin-dependent kinase 5 activator 1 | Homo sapiens (human) | 5.6667 | |
| G2/mitotic-specific cyclin-B3 | Homo sapiens (human) | 7 | |
| Cyclin-dependent kinase 1 | Oryzias latipes (Japanese medaka) | 5.2571 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bharate, SB; Raghuvanshi, R | 1 |
1 other study(ies) available for lestaurtinib and olomoucine
| Article | Year |
|---|---|
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |